Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cell.2021.03.028 http://scihub22266oqcxt.onion/10.1016/j.cell.2021.03.028 33761326!7962585!33761326     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell 2021 ; 184 (9): 2332-2347.e16 Nephropedia Template TP {{tp|p=33761326|t=2021. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 |pdf=|usr=}}{{33761326}} gab.com Text N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 JO: Cell http://www.kidney.de/pget.php?&tw=1&pmid=33761326 #FOAvip The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient plasma. Little is known about neutralizing Abs binding to epitopes outside the RBD and their contribution to protection. Here, we describe 41 human monoclonal Abs (mAbs) derived from memory B cells, which recognize the SARS-CoV-2 S N-terminal domain (NTD) and show that a subset of them neutralize SARS-CoV-2 ultrapotently. We define an antigenic map of the SARS-CoV-2 NTD and identify a supersite (designated site i) recognized by all known NTD-specific neutralizing mAbs. These mAbs inhibit cell-to-cell fusion, activate effector functions, and protect Syrian hamsters from SARS-CoV-2 challenge, albeit selecting escape mutants in some animals. Indeed, several SARS-CoV-2 variants, including the B.1.1.7, B.1.351, and P.1 lineages, harbor frequent mutations within the NTD supersite, suggesting ongoing selective pressure and the importance of NTD-specific neutralizing mAbs for protective immunity and vaccine design. Twit Text FOAVip N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 ????Cell http://www.kidney.de/pget.php?&tw=1&pmid=33761326 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33761326 #FOAvip English Wikipedia <ref>{{Cite pmid|33761326}}</ref> N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 #MMPMID33761326 McCallum M; De Marco A; Lempp FA; Tortorici MA; Pinto D; Walls AC; Beltramello M; Chen A; Liu Z; Zatta F; Zepeda S; di Iulio J; Bowen JE; Montiel-Ruiz M; Zhou J; Rosen LE; Bianchi S; Guarino B; Fregni CS; Abdelnabi R; Foo SC; Rothlauf PW; Bloyet LM; Benigni F; Cameroni E; Neyts J; Riva A; Snell G; Telenti A; Whelan SPJ; Virgin HW; Corti D; Pizzuto MS; Veesler D Cell 2021[Apr]; 184 (9): 2332-2347.e16 PMID33761326show ga The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient plasma. Little is known about neutralizing Abs binding to epitopes outside the RBD and their contribution to protection. Here, we describe 41 human monoclonal Abs (mAbs) derived from memory B cells, which recognize the SARS-CoV-2 S N-terminal domain (NTD) and show that a subset of them neutralize SARS-CoV-2 ultrapotently. We define an antigenic map of the SARS-CoV-2 NTD and identify a supersite (designated site i) recognized by all known NTD-specific neutralizing mAbs. These mAbs inhibit cell-to-cell fusion, activate effector functions, and protect Syrian hamsters from SARS-CoV-2 challenge, albeit selecting escape mutants in some animals. Indeed, several SARS-CoV-2 variants, including the B.1.1.7, B.1.351, and P.1 lineages, harbor frequent mutations within the NTD supersite, suggesting ongoing selective pressure and the importance of NTD-specific neutralizing mAbs for protective immunity and vaccine design. |Animals[MESH] |Antibodies, Monoclonal/chemistry/immunology[MESH] |Antibodies, Neutralizing/immunology[MESH] |Antigens, Viral/*immunology[MESH] |COVID-19/immunology/virology[MESH] |Cricetinae[MESH] |Epitope Mapping[MESH] |Genetic Variation[MESH] |Models, Molecular[MESH] |Mutation/genetics[MESH] |Neutralization Tests[MESH] |Protein Domains[MESH] |RNA, Viral/genetics[MESH]N-terminal domain antigenic mapping reveals a site of vulnerability fo(epmc).pdf DeepDyve Pubget Overpricing